News 03.12.2025 CUTISS is pleased to share that the 1-year results of the Phase IIb clinical trial evaluating denovoSkin™ in adolescent and adult burn patients have been published in eClinicalMedicine, part of The Lancet Discovery Science. The prospective, randomized, controlled multicenter study compared denovoSkin™ to split-thickness skin grafts, the current surgical standard. The...
News 02.12.2025 Schlieren (Zürich), Switzerland, December 2, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, today announced that the first patient has been enrolled in its global ASTRA (Ankle Subtalar arThrodesis Randomized Assessment) study. ASTRA is a prospective, randomized, single-blinded, controlled, multi-center study to assess the...
News 21.11.2025 CUTISS has been awarded 2nd place at the 2025 edition of The Spark – Der Deutsche Digitalpreis, which recognizes outstanding deep-tech innovation across Germany, Austria, and Switzerland. The award ceremony in Munich brought together finalists from across a range of industries. CUTISS was recognized for its pioneering work in personalized regenerative...
News 13.11.2025 SCHLIEREN, Switzerland--(BUSINESS WIRE)--Virometix AG, a clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced the completion of a $15 million financing round from existing shareholders. The funds will support continued clinical and development activities for V-212, Virometix’s lead serotype-independent pneumococcal vaccine candidate, currently in Phase I clinical evaluation. Proceeds from the financing...
News 12.11.2025 InSphero AG, the global market leader in 3D cell-based assays and organ-on-chip systems signed the definitive agreement to acquire DOPPL SA, a Lausanne-based innovator in the organoid space, including the Sun Bioscience Gri3D® technology. The acquisition strengthens InSphero’s position as the most comprehensive provider of advanced 3D in vitro models, combining scalable spheroid and organoid technologies with...